Top-Rated StocksTop-RatedNASDAQ:NTRA Natera (NTRA) Stock Price, News & Analysis → Does this make you sick? (From Allegiance Gold) (Ad) Free NTRA Stock Alerts $107.06 +0.75 (+0.71%) (As of 09:57 AM ET) Add Compare Share Share Today's Range$105.86▼$107.1150-Day Range$85.28▼$108.5052-Week Range$36.90▼$108.75Volume39,633 shsAverage Volume1.42 million shsMarket Capitalization$13.15 billionP/E RatioN/ADividend YieldN/APrice Target$98.47 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Natera alerts: Email Address Natera MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside7.4% Downside$98.47 Price TargetShort InterestBearish5.02% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.70Based on 15 Articles This WeekInsider TradingSelling Shares$29.21 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.44) to ($1.06) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.07 out of 5 starsMedical Sector780th out of 918 stocksMedical Laboratories Industry18th out of 20 stocks 2.5 Analyst's Opinion Consensus RatingNatera has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 15 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageNatera has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Natera's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.02% of the outstanding shares of Natera have been sold short.Short Interest Ratio / Days to CoverNatera has a short interest ratio ("days to cover") of 4.5.Change versus previous monthShort interest in Natera has recently increased by 7.12%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldNatera does not currently pay a dividend.Dividend GrowthNatera does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NTRA. Previous Next 2.6 News and Social Media Coverage News SentimentNatera has a news sentiment score of 0.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.43 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 15 news articles for Natera this week, compared to 6 articles on an average week.Search InterestOnly 7 people have searched for NTRA on MarketBeat in the last 30 days. This is a decrease of -13% compared to the previous 30 days.MarketBeat FollowsOnly 9 people have added Natera to their MarketBeat watchlist in the last 30 days. This is a decrease of -10% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Natera insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $29,214,503.00 in company stock.Percentage Held by InsidersOnly 7.60% of the stock of Natera is held by insiders.Percentage Held by Institutions99.90% of the stock of Natera is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Natera's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Natera are expected to grow in the coming year, from ($2.44) to ($1.06) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Natera is -34.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Natera is -34.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNatera has a P/B Ratio of 16.69. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Natera's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Allegiance GoldDoes this make you sick?The US Dollar Is "Finished" A deteriorating economy, global instability, and a weakened banking system have pushed the U.S. financial system to the brink, imperiling the value of your savings and investments.Get your Free Wealth Protection Kit About Natera Stock (NASDAQ:NTRA)Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.Read More NTRA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NTRA Stock News HeadlinesMay 18 at 9:33 AM | insidertrades.comNatera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman Sells 6,779 SharesMay 11, 2024 | insidertrades.comNatera, Inc. (NASDAQ:NTRA) Insider Sells $3,137,700.00 in StockMay 5, 2024 | insidertrades.comMichael Burkes Brophy Sells 1,866 Shares of Natera, Inc. (NASDAQ:NTRA) StockMay 2, 2024 | insidertrades.comNatera, Inc. (NASDAQ:NTRA) Insider John Fesko Sells 929 SharesApril 27, 2024 | insidertrades.comNatera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy Sells 705 SharesApril 24, 2024 | insidertrades.comInsider Selling: Natera, Inc. (NASDAQ:NTRA) Insider Sells 787 Shares of StockMay 19 at 5:24 AM | americanbankingnews.comSteven Leonard Chapman Sells 6,779 Shares of Natera, Inc. (NASDAQ:NTRA) StockMay 18 at 2:26 AM | americanbankingnews.comNatera, Inc. (NASDAQ:NTRA) Given Consensus Rating of "Buy" by AnalystsMay 17, 2024 | americanbankingnews.comNatera (NASDAQ:NTRA) Upgraded by StockNews.com to "Hold"May 16, 2024 | americanbankingnews.comNatera (NASDAQ:NTRA) PT Raised to $120.00May 15, 2024 | americanbankingnews.comNatera (NASDAQ:NTRA) PT Raised to $125.00 at BTIG ResearchMay 14, 2024 | americanbankingnews.comNatera (NASDAQ:NTRA) Given New $137.00 Price Target at TD CowenMay 13, 2024 | markets.businessinsider.comKey Takeaways From Natera Analyst RatingsMay 13, 2024 | americanbankingnews.comNatera (NASDAQ:NTRA) Price Target Raised to $117.00May 12, 2024 | seekingalpha.comNatera, Inc. (NTRA) Q1 2024 Earnings Call TranscriptMay 12, 2024 | americanbankingnews.comCanaccord Genuity Group Increases Natera (NASDAQ:NTRA) Price Target to $130.00May 12, 2024 | americanbankingnews.comDaniel Rabinowitz Sells 30,000 Shares of Natera, Inc. (NASDAQ:NTRA) StockMay 11, 2024 | finance.yahoo.comNatera Inc (NTRA) Surpasses Analyst Revenue Forecasts in Q1 2024May 11, 2024 | americanbankingnews.comStockNews.com Downgrades Natera (NASDAQ:NTRA) to SellMay 11, 2024 | americanbankingnews.comNatera (NASDAQ:NTRA) Reaches New 12-Month High After Earnings BeatMay 10, 2024 | benzinga.comWhy Natera Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving PremarketMay 10, 2024 | msn.comNatera, Inc. (NASDAQ:NTRA) Q1 2024 Earnings Call TranscriptMay 9, 2024 | msn.comNTRA Stock Earnings: Natera Beats EPS, Beats Revenue for Q1 2024May 9, 2024 | businesswire.comNatera Reports First Quarter 2024 Financial ResultsMay 7, 2024 | markets.businessinsider.comCraig-Hallum Keeps Their Buy Rating on Natera (NTRA)See More Headlines Receive NTRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Natera and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today5/20/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryN/A Current SymbolNASDAQ:NTRA CUSIPN/A CIK1604821 Webwww.natera.com Phone(650) 249-9090FaxN/AEmployees3,293Year FoundedN/APrice Target and Rating Average Stock Price Target$98.47 High Stock Price Target$137.00 Low Stock Price Target$68.00 Potential Upside/Downside-7.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage15 Analysts Profitability EPS (Most Recent Fiscal Year)($3.12) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-434,800,000.00 Net Margins-30.24% Pretax Margin-30.19% Return on Equity-49.72% Return on Assets-26.08% Debt Debt-to-Equity Ratio0.36 Current Ratio4.12 Quick Ratio3.98 Sales & Book Value Annual Sales$1.08 billion Price / Sales12.06 Cash FlowN/A Price / Cash FlowN/A Book Value$6.37 per share Price / Book16.69Miscellaneous Outstanding Shares122,800,000Free Float113,470,000Market Cap$13.05 billion OptionableOptionable Beta1.38 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesDr. Matthew Rabinowitz Ph.D. (Age 51)Co-Founder & Executive Chairman Comp: $441.58kMr. Steven Leonard Chapman (Age 45)CEO & Director Comp: $1.15MMr. Michael B. Brophy M.B.A. (Age 44)Chief Financial Officer Comp: $611.35kMr. Daniel Rabinowitz L.L.M. (Age 55)Secretary & Chief Legal Officer Comp: $566.03kMr. John FeskoPresident & Chief Business OfficerMr. Jonathan Sheena M.Eng. (Age 51)Co-Founder & Director Comp: $293.91kMs. Olesya A. Anisimova CPAChief Accounting OfficerMr. Rishi KackerChief Technology OfficerMr. Eric A. EvansChief Scientific OfficerMr. Jerry DiffleyChief Compliance & Privacy OfficerMore ExecutivesKey CompetitorsQuest DiagnosticsNYSE:DGXExact SciencesNASDAQ:EXASLaboratory Co. of AmericaNYSE:LHRadNetNASDAQ:RDNTFresenius Medical CareNYSE:FMSView All CompetitorsInsiders & InstitutionsVirtu Financial LLCBought 7,736 shares on 5/20/2024Ownership: 0.006%Castleark Management LLCBought 74,630 shares on 5/17/2024Ownership: 0.061%Comerica BankBought 12,202 shares on 5/17/2024Ownership: 0.012%Walleye Trading LLCBought 500 shares on 5/17/2024Ownership: 0.000%Kennedy Capital Management LLCBought 3,190 shares on 5/16/2024Ownership: 0.003%View All Insider TransactionsView All Institutional Transactions NTRA Stock Analysis - Frequently Asked Questions Should I buy or sell Natera stock right now? 15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Natera in the last year. There are currently 15 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" NTRA shares. View NTRA analyst ratings or view top-rated stocks. What is Natera's stock price target for 2024? 15 analysts have issued 12-month price objectives for Natera's stock. Their NTRA share price targets range from $68.00 to $137.00. On average, they predict the company's stock price to reach $98.47 in the next year. This suggests that the stock has a possible downside of 7.4%. View analysts price targets for NTRA or view top-rated stocks among Wall Street analysts. How have NTRA shares performed in 2024? Natera's stock was trading at $62.64 at the beginning of the year. Since then, NTRA shares have increased by 69.7% and is now trading at $106.31. View the best growth stocks for 2024 here. When is Natera's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our NTRA earnings forecast. How were Natera's earnings last quarter? Natera, Inc. (NASDAQ:NTRA) posted its quarterly earnings results on Thursday, May, 9th. The medical research company reported ($0.56) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.72) by $0.16. The medical research company earned $367.70 million during the quarter, compared to analysts' expectations of $316.31 million. Natera had a negative trailing twelve-month return on equity of 49.72% and a negative net margin of 30.24%. Natera's revenue for the quarter was up 52.1% compared to the same quarter last year. During the same quarter last year, the company earned ($1.23) earnings per share. What ETFs hold Natera's stock? ETFs with the largest weight of Natera (NASDAQ:NTRA) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), Alger Mid Cap 40 ETF (FRTY), Pinnacle Focused Opportunities ETF (FCUS), Alger 35 ETF (ATFV), First Trust NYSE Arca Biotechnology Index Fund (FBT), Franklin Genomic Advancements ETF (HELX) and Invesco Dorsey Wright Healthcare Momentum ETF (PTH). What guidance has Natera issued on next quarter's earnings? Natera issued an update on its FY 2024 earnings guidance on Thursday, May, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.4 billion-$1.5 billion, compared to the consensus revenue estimate of $1.3 billion. What is Steve Chapman's approval rating as Natera's CEO? 158 employees have rated Natera Chief Executive Officer Steve Chapman on Glassdoor.com. Steve Chapman has an approval rating of 91% among the company's employees. This puts Steve Chapman in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Natera own? Based on aggregate information from My MarketBeat watchlists, some companies that other Natera investors own include Xtrackers California Municipal Bond ETF (CA), BlackRock (BLK), Endologix (ELGX), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), NIC (EGOV), Aegean Marine Petroleum Network (ANW), Micron Technology (MU), Transocean (RIG) and Allergan (AGN). When did Natera IPO? Natera (NTRA) raised $101 million in an IPO on Thursday, July 2nd 2015. The company issued 6,300,000 shares at $15.00-$17.00 per share. Morgan Stanle, Cowen and Company and Piper Jaffray served as the underwriters for the IPO and Baird and Wedbush Pacgrow were co-managers. Who are Natera's major shareholders? Natera's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (9.15%), Kynam Capital Management LP (1.63%), Principal Financial Group Inc. (1.13%), Allspring Global Investments Holdings LLC (0.71%), Allspring Global Investments Holdings LLC (0.71%) and Price T Rowe Associates Inc. MD (0.55%). Insiders that own company stock include Daniel Rabinowitz, Gail Boxer Marcus, Herm Rosenman, James Healy, John Fesko, Jonathan Sheena, Matthew Rabinowitz, Michael Burkes Brophy, Patrick J Donovan, Robert Alan Schueren, Roelof Botha, Rowan E Chapman, Solomon Moshkevich, Steven Leonard Chapman, Todd C Cozzens and Todd C Cozzens. View institutional ownership trends. How do I buy shares of Natera? Shares of NTRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NTRA) was last updated on 5/21/2024 by MarketBeat.com Staff From Our PartnersNext President (Not Trump. Not Biden.)The Freeport SocietyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsDoes this make you sick?Allegiance Gold[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Crypto 101 Media4 Cryptos BETTER than BitcoinTrue Market InsidersBill Gates is all about this tiny $2 stockTimothy SykesThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldDid You Get Your Free Bitcoin Yet?Crypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Natera, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
